Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Case Western Reserve University and Richmond, Calif.-based Sangamo Therapeutics Inc. (Nasdaq: SGMO) announced they have received an $11 million grant from the National Institutes of Health for a study of gene-edited T cells.
The study is designed to”eradicate persistent HIV infection in patients receiving anti-retroviral therapy, a combination of medicines that slows the rate at which HIV replicates,” Case Western Reserve and Sangamo said in a news release issued Wednesday morning, Feb. 7.
Click here to read the complete article.
Originally published February 7, 2018.